Latest posts
Page 10 of 26
New 2009 NICE clinical guideline for the treatment of rheumatoid arthritis
The UK’s National Institute for Health and Clinical Excellence (NICE) issued in February 2009 an update of the rheumatoid arthritis guideline. Pharmacist Matt Robinson at his excellent “Prescribing advice for GP’s” commented the most relevant points of the guidance: This guideline recommends that treatment is started early during active disease in order to minimise damage
Etravirine (Intelence) for HIV infection: not recommended by the Scottish Medicines Consortium
This is an excerpt from the Scottish Medicines Consortium (SMC) advice on etravirine (Intelence). ADVICE: following a full submission etravirine (Intelence), in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is not recommended for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced
PowerPoint presentation on cardiovascular pharmacology for nurses. Drugs to treat hypertension, heart failure, MI, shock and arrhythmias reviewed
The following cardiovascular pharmacology presentation is a practical overview on hypertension, drugs used in heart failure, MI, shock and antiarrhythmics: More on nursing pharmacology
Direct-to-consumer advertising (DTCA): the case of the serotonin hypothesis and SSRIs ads
I would like to recommend Pharmamotion readers one of the most popular articles in PLoS Medicine: Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. Jeffrey R. Lacasse, Jonathan Leo The article is a definitely a must read for those interested in direct-to-consumer advertising (DTCA) issues. However,for those who don’t have enough
MHRA: Tibolone (Livial) increases risk of breast cancer recurrence
The Medicines and Healthcare products Regulatory Agency (UK) warned in the February 2009 Drug Safety Advice about the increased breast cancer recurrence in patients treated with tibolone (Livial): Treatment for breast cancer (e.g., tamoxifen) can commonly exacerbate menopausal symptoms. Although tibolone is contraindicated in women with known or suspected breast cancer, and in those with
Zonisamide (Zonegran): FDA warns about risk of metabolic acidosis and issues recommendations
The FDA issued an alert (February 23, 2009) about the risk of metabolic acidosis in patients treated with zonisamide (Zonegran). An excerpt from the alert on this anticonvulsant adverse effect: Following a review of updated clinical data, the FDA has determined that treatment with zonisamide can cause metabolic acidosis in some patients. Zonisamide is indicated
Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs
An excerpt from the Drug Advice issued by the Scottish Medicines Consortium on adalimumab (Humira): adalimumab (Humira) is accepted for restricted use in NHS Scotland, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17 years who have an inadequate response to one or more disease-modifying anti-rheumatic drugs
PowerPoint presentation: ACE inhibitors, ARBs, and calcium channel blockers
The following pharmacology PowerPoint has been developed by Ed Sheridan, Pharm.D. Outline: ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), and calcium channel blockers •Review the Mechanism of Action •Review Safety •Review Efficacy •Hypertension Download ppt slides: pharmacology of ACEi, ARBs, and Calcium channel blockers. You may also find interesting related PowerPoint presentation on drug therapy
EMEA recommends new contraindication for aliskiren (Rasilez): angioedema
According to the EMEA, aliskiren (Rasilez, Tekturna in the USA) should not be prescribed in patients that experienced angioedema after taking the drug. Some excerpts from the EMEA press release dated 19 February, 2009: The European Medicines Agency (EMEA) has recommended adding a contraindication to the Product Information for aliskiren, stating that it must not
Endocrine drugs flash cards
Endocrine pharmacology flash cards by Department of Pharmacology at University of Utah.Bisphosphonates,insulins, antidiabetic agents, antithyroid drugs.
USMLE video lecture review on propofol
Video review on chemistry, mechanism of action and pharmacokinetics of propofol (short-acting intravenous sedative agent, used for the induction of general anesthesia). Quite useful when you get tired of studying pharmacology.
Cardiovascular MCQs for pharmacology review. USMLE style questions on antiarrhythmics
Pharmacology questions on antiarrhythmics. USMLE style MCQs for pre- test review. Developed by UMKC School of Medicine.
Efalizumab (Raptiva) for plaque psoriasis. EMEA recommends withdrawal of its marketing authorization, FDA issues public health advisory
Raptiva and progressive multifocal leukoencephalopathy : EMEA recommends withdrawal of marketing authorization and FDA recommends monitoring patients.
Drug development approval process. PowerPoint presentation and CME credit available
Southern Collaboration in Research to Impact Prescription of Therapeutics (SCRIPTS) is a project aimed to”help prescribers enhance their ability to evaluate drug related information to improve their prescribing practices and describe proper prescribing practices to improve quality of patient care”. It is sponsored by University of Alabama at Birmingham. This is the first module concerning
USMLE-like questions on antihypertensives
These questions from the UMKC School of Medicine have a different degree of difficulty, but are useful to review pharmacology of hypertension. Antihypertensives Item Number: 11201 correct answer: 4 category: Antihypertensives 1. Gynecomastia, hyperkalemia, and menstrual abnormalities are potential adverse effects associated with: A. amiloride B. captopril C. triamterene D. spironolactone 1. A,B,C 2. A,C